A Study to Collect Blood and Saliva Samples from Participants Diagnosed with Cancer and from Non-Cancerous Participants Saliva Specimens

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 12-005219
    Sponsor Protocol Number: 12-005219

About this study

The purpose of this research is to collect blood and saliva samples from participants already diagnosed with cancer and from non-cancerous participants. The blood and saliva specimens obtained during this research will be processed to look for proteins, protein products, and genetic markers of cancer treatments - that can be identified in blood and saliva specimens.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria

  • Subjects diagnosed with cancer:
    • Age 18-100
    • Subjects either with a histological confirmed diagnosis of cancer or a history of previous cancer specific treatment destined to initiate hormonal, biological, and/or chemotherapy treatments. This includes cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician or after failure of therapy.
    • Subjects with a histological confirmed diagnosis of cancer who are destined to initiate standard of care therapeutic interventions.This includes cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician.
    • Subjects with non-localized cancer being followed or treated at Mayo Clinic as part of standard clinical care.
    • Subject must be able to sign informed consent document.
  • Subjects not undergoing cancer treatment:
    • Age 18-100
    • Subject may be diagnosed with cancer, but not currently undergoing cancer treatment. Information pertaining to treatment status will be obtained from patient, and confirmed in medical record subsequent to completing the informed consent process (if information is available).
    • Subject must be able to sign informed consent document.

Exclusion Criteria: 

  • Subjects who are incarcerated or display signs of limited decision making capacity as assessed by study personnel;
  • Subjects clinically judged to be at increased risk of bleeding from phlebotomy;

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Diasio, M.D.

Contact us for the latest status

Contact information:

Calvin Jerde

(507)538-6678

Jerde.Calvin@mayo.edu

.
CLS-20317677

Mayo Clinic Footer